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Abstract
Introduction Thrombotic events are a common and severe
complication of endovascular aneurysm treatment with
significant impact on patients’ outcome. This study evaluates
risk factors for thrombus formation and assesses the efficacy
and safety of abciximab for clot dissolution.
Materials and methods All patients treated with abciximab
during (41 patients) or shortly after (22 patients) intracranial
aneurysm coil embolisation were retrieved from the institution-
al database (2000 to 2007, 1,250 patients). Sixty-three patients
(mean age, 55.3 years, ±12.8) had received either intra-arterial
or intravenous abciximab. Risk factors for clot formation were
assessed and the angiographic and clinical outcome evaluated.
Results No aneurysm rupture occurred during or after
abciximab application. The intra-procedural rate of total
recanalisation was 68.3%. Thromboembolic complications
were frequently found in aneurysms of the Acom complex and
of the basilar artery, whilst internal carotid artery aneurysms
were underrepresented. Two patients died of treatment-related
intracranial haemorrhages into preexisting cerebral infarcts.
Two patients developed a symptomatic groin haematoma.
Conclusions Abciximab is efficacious and safe for throm-
bolysis during and after endovascular intracranial aneurysm
treatment in the absence of preexisting ischaemic stroke.
Keywords Abciximab . Aneurysm . Endovascular
treatment . Thromboembolic complication
Introduction
Thromboembolic events during or immediately after the
endovascular treatment of intracranial aneurysms occur in
3–6% of procedures [1–5]. Heparin is used in most centres
during aneurysm treatment to prevent thromboembolic
events, either as a bolus or in the saline flushes of the
catheters [1, 6, 7]. Furthermore, many centres apply aspirin
and/or clopidogrel before or during intervention to reduce
thromboembolic events.
However, permanent neurological disability caused by
procedure-related ischaemic events still occurs in 1.7–5%
of the patients [1, 8].
The identification of risk factors for thrombus formation
may facilitate the adjustment of peri-interventional anti-
coagulation to reduce embolic events. A safe and effica-
cious treatment of thrombotic vessel occlusion may also
improve patients’ outcome. Various approaches have been
advocated in the past including mechanical disruption of
the thrombus [9] and application of fibrinolytic drugs [10].
Some studies have investigated the efficiency and safety of
the glycoprotein IIb/IIIa antagonists Tirofiban or Eptifiba-
tide [11–13]. Recently, several case reports [14–16] and
smaller clinical studies [1, 9, 17, 18] have suggested good
recanalisation rates following the use of the glycoprotein
IIb/IIIa antagonist abciximab. However, the application
route, dosage and timing vary (Table 1).
The risk of aneurysm re-bleed is of utmost concern if
abciximab is used to treat clot formation in acutely ruptured
aneurysms. This study evaluates risk factors for procedural
clot formation during the endovascular treatment of
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cerebral aneurysms and assesses the safety of abciximab
application in 63 patients.
Materials and methods
Patients who underwent endovascular aneurysm treatment
and received abciximab in our department were retrieved
from a database of 1,250 patients. We found 63 cases which
represented the sample of our study, and all following
relative values are derived from these. In addition, the
medical records and imaging studies were reviewed.
Our centre has a neurosurgical service; the decision for
the endovascular or open surgical approach is based on a
consensus between neurosurgeon and interventionalist.
The indication for treatment of an unruptured aneurysm
was based on individual decisions, either based on the size
and location and, therefore, the rupture risk of the aneurysm
or on the neurological symptoms if present.
All procedures were performed by an experienced neuro-
radiologist under general anaesthesia using the spectrum of
standard devices and procedures.
In most centres, anticoagulation before and during
intervention and especially treatment of thromboembolic
complications is not established by the application of a
single drug.
In our department, a heparin bolus (5,000 IU) was
routinely administered during intervention, and the
catheters were flushed continuously with heparinised
sodium chloride solution (5 IU/ml). The activated
clotting time was monitored (Hemochrom Response,
ITC, New York, USA) in an attempt to achieve doubled
baseline levels during the procedure. In five patients, the
initial bolus of heparin did not achieve double baseline
levels, and an additional bolus of 2,000 IU heparin was
given. Seven patients received pre-medication with aspirin;
in ten cases, aspirin was given during intervention, in seven
cases in combination with clopidogrel.
All patients received abciximab (ReoPro, Eli Lilly,
Indianapolis, USA) either as a slow intra-arterial or
intravenous hand injection (intra-procedural) or infusion
(post-procedural). Two patients received an additional dose
of 5 mg recombinant tissue plasminogen activator (rt-PA).
For further analysis, the patients were divided as
follows: The first group includes patients with thromboem-
bolic complications during the procedure. The thrombus
formation was documented angiographically and treated
immediately. Abciximab was injected either intra-arterially
via the microcatheter/guide catheter or intravenously
through a peripheral line. If the thromboembolic event
occurred either adjacent or downstream to the aneurysm,
the success of the abciximab application was demonstrated
angiographically and rated as complete, partial or lacking.
In one patient, abciximab was given for thrombus forma-
tion in the basilar artery before the treatment of a ruptured
posterior cerebral artery aneurysm. In all other patients, at
least one coil was in place at the time abciximab was
administered.
The second group comprised patients without thrombus
formation during the intervention that developed focal
neurological deficits suggestive of thromboembolic events
from the aneurysm within 12 h. After intracranial haemor-
rhage (ICH) was excluded by computed tomography (CT),
these were treated with a 20- to 30-min infusion of
abciximab intravenously. The recanalisation was not docu-
mented angiographically. This protocol has been has been
abandoned and the authors do not advocate this protocol.
The size of the aneurysm neck was measured on the 3D
angiogram and/or the CT angiography (CTA) and classified
as small (neck diameter ≤4 mm) or broad (>4 mm). This
value is proportional to the neck–vessel interface and can
therefore be considered as a measure for the coil–blood
interface.
Angiographic recanalisation was graded into: total,
subtotal and unchanged thrombus formation. The clinical
outcome was assessed at discharge according to the
modified Rankin scale (mRS). In some cases, additional
devices (e.g. stent, balloon remodelling) were used during
aneurysm treatment procedures. The risk of thromboembolic
complications in these patients was recorded.
Student’s t test and odds ratio and 95% confidential interval
(95% CI) were used for between-group analysis. Mann–
Whitney test was applied for comparison of recanalisation
grading.
Results
In 63 patients (5% of all 1,250 records), a thromboembolic
complication occurred which was serious enough to
warrant thrombolytic treatment with abciximab (39 women
Table 1 Studies on abciximab during endovascular aneurysm
treatment.
Study No. of
patients
Route of
administration
Intracranial
haemorrhagic
complications
Mounayer et al. 2003 [1] 13 ia –
Song et al. 2004 [17] 7 ia [1]a
Aviv et al. 2005 [18] 13 iv –
Velat et al.b 2006 [9] 29 ia + iv 3
Present study 63 ia/iv 2
a Leakage of contrast material, no symptomatic ICH
b Study included different intracranial endovascular procedures
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and 24 men, mean age 55.3 years, ±12.8). The initial mean
World Federation of Neurological Surgeons score was 1.6
(range 0–5, ±1.2). In 51 patients (81%), the aneurysm had
ruptured within the last 28 days. The median interval
between ictus and treatment was 5 days (range 0–28, ±4.8).
Ten patients (16%) were treated for an unruptured aneurysm
(seven incidental, three coincidental). Two further patients
(3%) received delayed aneurysm treatment (>6 months) after
a previous subarachnoid haemorrhage (SAH) and were
considered as unruptured. The mean dose of abciximab
was 12.7 mg (range 2–30, ±5.6).
The localisation of aneurysms showed the following
distribution: The Acom complex (A1, A2 and Acom) was
affected in 27 patients (42%), the middle cerebral artery in
12 patients (19%) and the basilar artery in 11 patients
(17.5%). Rare locations included the Pcom (four patients,
6.3%), the pericallosal artery (three patients, 4.8%), the
internal carotid artery (ICA; three patients, 4.8%), the Pica
(two patients, 3.2%) and the posterior cerebral artery (one
patient, 2.6%). In 40 aneurysms (63.5%), the neck was
<4 mm in diameter, in 23 aneurysm (36.5%) 4 mm or
larger.
Coiling was assisted by additional devices in 14 patients
(17.5%). These were 11 balloon-remodelling procedures,
two Trispan applications and one intravascular stent
placement. An ICH was not found in the small subgroup
of patients treated with additional devices.
Of the 41 patients (mean age 54.9 years, ±13.4) with intra-
procedural clot formation, 27 patients received abciximab
intra-arterially and 12 intravenously. Two patients received it
both intra-arterially and intravenously. A mean dose of
13.5 mg abciximab was given (range 2–30, ±13.5). In 35
patients (85.4%), the thromboembolic events were adjacent to
the aneurysm or downstream. In six patients (14.6%), other
territories were involved.
The abciximab administration completely resolved the
obstruction in 28 of 41 patients (68.3%, case illustration,
Fig. 1). In eight of 41 patients (19.5%), the application led
to a subtotal recanalisation, and in five of 41 patients
(12.2%), the thrombus remained unchanged (Table 2). No
significant difference was found in the recanalisation rates
between intra-procedural IV and IA application. The mean
mRS score at discharge was 1.4.
In the group of patients with intraprocedural administra-
tion of abciximab, eight patients were additionally treated
with anti-platelet medication. No significant differences in
recanalisation rate were found for this small subgroup.
Twenty-two patients (mean age 56.1 years, ±11.9) received
abciximab during the immediate post-interventional course
(mean dose 11.3 mg, range 7.5–20, ±3.6 mg). The two groups
did not differ significantly in the mean dose of abciximab
(P<0.005). Fifteen of the 22 patients (68%) improved
significantly after delayed i.v. administration of abciximab.
In seven patients (32%), the neurological deficit remained
unchanged. The mean mRS score at discharge was 1.9.
Two patients (3.2%) suffered a fatal ICH after the
endovascular procedure, one after intra-procedural abciximab
and the other after post-procedural application of abciximab.
The first of these, a 48-year-old female patient, had been
treated with balloon remodelling for a coincidental unruptured
basilar artery termination aneurysm. Two hours after uncom-
plicated coiling, the patient developed severe left-sided
hemiparesis. After a haemorrhage had been excluded by CT,
the patient received 20 mg of abciximab intravenously. The
Fig. 1 Successful recanalisation using abciximab. After deployment
of the second coil during endovascular treatment of an Acom
aneurysm, the angiogram reveals thrombus formation in the adjacent
A2 segment of the left ACA (a). Within 5 min (b), the thrombus
propagates into both A2 segments (c) and leads to a total occlusion.
The immediate application of intra-arterial thrombolysis achieves a
fast recanalisation (d) and prevents post-interventional neurological
deficits in this 62-year-old female patient
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follow-up CT 4 h later demonstrated a large right-hemispheric
haemorrhage including thalamus and basal ganglia.
The second fatal bleed occurred into the cerebellum of a
59-year-old patient 6 h after coiling of a Pica aneurysm
(Fig. 2) and the administration of 3 mg abciximab.
Retrospective analysis revealed that the haemorrhages
had occurred into infarcted brain tissue and were not caused
by re-rupture of the aneurysm.
Two patients (3.2%) developed a large and symptomatic
groin haematoma, which in one patient developed into a
false aneurysm. Other haemorrhagic complications such as
gastrointestinal or retroperitoneal complications were not
encountered.
Discussion
Thrombus formation is the most common complication during
endovascular aneurysm treatment and may significantly
impact on the clinical outcome.
The identification of risk factors for thrombus formation
with the consequent adjustment of peri-interventional anti-
coagulation and the safe and efficient treatment of
thrombotic events may both improve patients’ outcome.
This study evaluates predisposing factors for clot
formation and assesses the safety and efficacy of abciximab
for its treatment.
Predisposing factors for thromboembolic complications
In our patient group, the most frequent site of clot
formation was the treated aneurysm or downstream to the
aneurysm (85.4%), and not the catheter system. Little data
are available on the risk factors for thrombus formation at
the blood–coil interface [7].
In our study, 36.5% of the thromboembolic complications
occurred during the treatment of wide-necked aneurysms,
whereas the majority (63.5%) were encountered during the
embolisation of aneurysms with a neck diameter ≤4 mm.
Hence, neck size does not appear to be the sole determining
factor of thrombus formation. Other factors contributing to
thrombosis may include manipulation within the aneurysm
and blood flow alteration by catheters or balloons. The
propensity of additional devices (e.g. stent, balloon) to
induce thromboembolic complications is still under debate.
Although some previous studies reported a higher incidence
of thromboembolic complications [4, 19] if these were used,
we did not find a significant difference. These results are in
Fig. 2 Fatal intracranial haemorrhage into a preexisting ischaemic
area. The patient was treated with a balloon-assisted coiling of a wide-
necked Pica aneurysm 5 days after SAH. During intervention,
thrombus formation is noted in the proximal Pica adjacent to the
aneurysm (b). In addition to mechanical disruption attempts, the
thrombus formation is treated locally during intervention with 3 mg of
abciximab through the microcatheter resulting in thrombus resolution
(c). Six hours later, the patient deteriorates, and a CT scan
demonstrates an intra-cerebellar haematoma (d). The retrospective
evaluation of the pre-interventional CTA reveals a hypodense region in
the right cerebellum (a), presumably a preexisting subacute ischaemic
lesion. No further SAH or signs of a re-rupture of the aneurysm were
found
Table 2 Recanalisation
results. Route of administration No. of
patients
Mean age (year) Mean dose in
mg (range)
Recanalisation No. of ICH
Intraprocedural 41 54.9 13.5 (2–30) 1
Complete, 68.3%
Subtotal, 19.5%
No., 12.5%
Postprocedural 22 11.3 (7.5–20) 1
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line with the findings of Layton at al. [20]. The application
of additional devices did not increase the risk of ICH.
Among all our patients, a predisposing factor for clot
formation seems to be aneurysm location. Aneurysms of
the Acom complex (42%) and the basilar artery (17.5%) led
most frequently to thrombus formation requiring treatment.
These numbers are in excess of the natural distribution of
aneurysms among our patients. Reviewing the data of
previous studies, Aviv et al. [18] reported five Acom
aneurysms (38.5%) in a series of 13. In another publication,
Velat et al. [9] found clot formation in ten basilar artery
aneurysms (38.5%) among a total of 26. The number of
thromboembolic complications during the treatment of ICA
lesions is surprisingly low (4.8%).
The high rate of thrombus formation in the treatment of
aneurysms of the Acom complex and the basilar artery may
be due to slow or turbulent flow, further impaired by
endovascular equipment.
The female predominance in the present study (62% female
patients) may not represent a sex-related predisposition for
thromboembolic complications, as this could solely reflect the
female predominance of aneurysms in general [21].
Efficacy and safety of abciximab
In most centres, anticoagulation before and during inter-
vention and especially treatment of thromboembolic com-
plications is not established by the application of a single
drug. In our study, all patients received a pre-interventional
bolus of heparin, a total of 17 patients received aspirin, and
seven patients additionally received clopidogrel. In two
cases, an additional dose of 5 mg rt-PA was applied.
Therefore, as a limitation of the study, the clinical setting
does not allow distinguishing between the effect of
abciximab alone and the effect of the combination of drugs.
The long-term outcome in patients after SAH mainly
depends on haemorrhage-related complications. Hence, the
impact of intra-procedural thrombolysis of patient outcome
is difficult to quantify in small studies. Our series, which is
the largest study so far, confirms the results of previous
studies [9, 17].
Using angiographic and clinical criteria, we consider
abciximab as an effective drug for the treatment of
thrombotic complications during and after aneurysm coiling
with complete recanalisation or clinical improvement in
68% of the patients.
Table 1 summarises previous reports on abciximab.
There is no consensus on the most effective application
route for the drug in literature nor did we see any difference
between intra-arterial and intravenous delivery. Although
intra-arterial injection yields higher drug concentrations at
the thrombus, this has not been shown to result in better
clinical efficiency. High systemic activity after intravenous
injection may be sufficient to achieve the same effect.
Abciximab blocks approximately 80% of all GPIIb/IIIa
receptors and disables platelet function for 48 h [22, 23]. The
delayed administration of abciximab in patients with neuro-
logical symptoms after the intervention proved to be less
effective. As previously mentioned, the protocol of delayed
administration of abciximab without prior angiographic
evaluation has been abandoned. CTA or catheter angiograms
are widely available now to investigate the underlying cause
of novel neurological deficits in the post-interventional course
(e.g. vasospasm).
The application of a thrombolytic drug during the
treatment of an acutely ruptured aneurysm may resolve
the thrombus but bears the risk of a fatal haemorrhage.
The interest focuses on the treatment strategy with the
best risk-to-benefit ratio. Various drugs have been used and
reported in small case series. Cronqvist et al. [10] reported a
high re-rupture and ICH rate leading to a poor neurological
outcome in patients treated with urokinase during aneurysm
coiling. The focus has since shifted to antiplatelet drugs, as
it emerges that procedural complications [6, 24] are often
caused by platelet-rich thrombi.
First reports have suggested a good recanalisation rate for
abciximab. This chimeric and monoclonal human murine
antibody binds to the GPIIb/IIIa receptor. It inhibits platelet
aggregation and platelet binding to fibrinogen and dissolves
thrombi [25–27]. However, the effect of abciximab can only
be antagonised by platelet substitution.
In the present study, none of the 51 ruptured and 12
unruptured aneurysms bled during or after the application
of abciximab. Two patients suffered a fatal ICH, both into
distant parts of the brain, probably into subacute infarcts.
The reasons for this selective effect of abciximab on clot
formation are difficult to understand. One reason might be the
changes in haemodynamics within the aneurysm due to the
coil. Furthermore, the thrombus sealing the ruptured aneurysm
may differ from the clot complicating the treatment, with the
thrombus sealing the aneurysm having matured and stabilised
to contain a high amount of fibrin. Therefore, abciximab may
be less effective at destabilising this crucial clot component
than a fibrinolytic drug-like urokinase.
Recent data indicate that the administration of abciximab
in the treatment of patients’ acute ischaemia increases the
risk of symptomatic and fatal ICH [28]. The number of
patients evaluated in our study is comparably low; however,
we did not observe an increased rate of ICH in this
hyperacute setting of ischaemic cerebral stoke. Haemor-
rhages occurred in patients with subacute ischaemic brain
areas. The differences between the findings in acute stroke
patients and patients with thromboembolic events during
endovascular treatment might be explained by the time window
between vessel occlusion and administration of abciximab.
This time span during endovascular treatment is in the range of
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minutes compared to the treatment of acute stroke patients. The
short ischaemic interval might be a possible explanation for the
low rate of reperfusion injury and ICH.
Two patients developed a symptomatic groin haema-
toma; one required interventional treatment. This is a well-
established complication of abciximab reported in the
interventional cardiology literature [29].
We can conclude that the application of abciximab for
thrombotic complications of aneurysm treatment is effective
and safe in the absence of subacute ischaemic stroke.
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